Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 25

Results For "Shares"

324 News Found

Ube to buy API Corp. from Mitsubishi Chemical
News | August 09, 2022

Ube to buy API Corp. from Mitsubishi Chemical

APIC is a contract development and manufacturing organization (CDMO) that offers a wide range of services such as synthetic route design, pilot manufacturing, investigational medical manufacturing, and commercial production, by making full use of integrated processes that combine organic synthesis technologies and biotechnologies it has cultivated over many years


GSK’s Haleon begins trading in LSE
News | July 20, 2022

GSK’s Haleon begins trading in LSE

Completion of the demerger of Haleon and share consolidation of GSK


Healthcare Triangle closes $6.5 million private placement
News | July 15, 2022

Healthcare Triangle closes $6.5 million private placement

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.


Cipla to further invest Rs 25.90 crore to acquire 22.02% stake in GoApptiv
Digitisation | June 28, 2022

Cipla to further invest Rs 25.90 crore to acquire 22.02% stake in GoApptiv

Strengthens investment in channels of the future to expand patient reach


Medix Biochemica acquires Bioresource Technology
News | June 21, 2022

Medix Biochemica acquires Bioresource Technology

Bioresource Technology's state of the art manufacturing facility in Weston, Florida


Aurobindo Pharma board approves acquisition of GLS Pharma
News | June 20, 2022

Aurobindo Pharma board approves acquisition of GLS Pharma

The company has a total sales of Rs. 25.8 crore during FY 21-22 and Rs. 26.4 crore during FY 20-21.


CCI approves sale of biosimilars portfolio of Viatris to Biocon Biologics
News | June 15, 2022

CCI approves sale of biosimilars portfolio of Viatris to Biocon Biologics

The proposed transaction involves the sale of the global biosimilars portfolio of Viatris to Biocon Biologics


Proxygen and Merck collaborates to develop molecular glue degraders
News | June 06, 2022

Proxygen and Merck collaborates to develop molecular glue degraders

The companies will jointly identify and develop molecular glue degraders up to a clinical candidate stage.